BIOARRAY is a molecular diagnostics company focused on fundamentally changing the paradigm of cancer treatment
BIOARRAY developed an intelligent proprietary platform of unique genes, focused on critical areas of oncology drug discovery and development. The platform leverages unique RNA biomarkers, phenotypic signatures, and proprietary algorithms to provide distinct valuable information regarding oncology drug sensitivity and resistance, development of predictive tests, and patient selection strategy for a range of treatments including targeted therapies, immuno-oncology drugs, and chemotherapies.
BIOARRAY predictive tests are designed to transform cancer treatment management, improve patient quality of life and survival outcomes, as well as reduce healthcare costs associated with unnecessary treatment. One of the leading issues in healthcare today is avoiding over treatment and determining the optimal treatment plan for cancer patients of all stages. Identifying relevant treatment options upfront means avoiding harmful side effects from ineffective treatment with the opportunity to improve outcomes by providing clinically actionable results to guide treatment decisions.
Learn more about BIOARRAY and our high-value, proprietary product portfolio: